e-ISSN 2148-0532 DOI 10.54233 Open Access · CC BY-NC-SA 4.0 Türkçe
Endoüroloji Bülteni — Endourology Bulletin Submit Manuscript
Original Article Open Access

Impact of pT1a–pT1b Substaging on Recurrence and Progression in High-Grade T1 Bladder Cancer

Yüksek Dereceli T1 Mesane Kanserinde pT1a–pT1b Alt Evrelemenin Nüks ve Progresyon Üzerine Etkisi

Author information
  1. Gaziosmanpaşa Eğitim ve Araştırma Hastanesi
Issue
Volume 18 · Issue 2
Pages
90-99
Published
May 29, 2026
DOI
https://doi.org/10.54233/endourolbull-1841585 (opens in a new tab)

Abstract

Objective: To evaluate the prognostic impact of pT1a–pT1b substaging on recurrence and progression in patients with high-grade T1 bladder cancer and to determine whether substaging serves as an independent predictor when assessed alongside established clinical and pathological risk factors.

Materials: and Methods: This retrospective, single-center cohort study included patients diagnosed with high-grade pT1 urothelial carcinoma who underwent transurethral resection of a bladder tumor (TURBT) between January 2017 and March 2025. Cases with ≥pT2 disease, other malignancies, the Bacillus Calmette-Guérin (BCG) contraindications, treatment non-compliance, incomplete follow-up, or trigonal tumors with unreliable muscularis mucosa assessment were excluded. Demographic, clinical, pathological, and follow-up data were extracted from institutional records. Recurrence and progression were defined according to standard criteria. Substaging was performed by experienced uropathologists. Survival outcomes were analyzed using the Kaplan–Meier method, and independent predictors were identified by multivariate Cox regression.

Results: Of 152 patients, 110 (72.4%) were classified as pT1a and 42 (27.6%) as pT1b. Carcinoma in situ (CIS) and tumor size ≥3 cm were significantly more frequent in pT1b cases. In multivariate analysis, CIS and tumor size ≥3 cm were independent predictors of both recurrence and progression. Although pT1b substaging was associated with worse recurrence-free survival on Kaplan–Meier analysis, it was not an independent predictor of recurrence in the Cox model; however, it independently predicted progression (HR=3.38). Kaplan–Meier analyses also demonstrated significantly worse progression-free survival in the pT1b group.

Conclusion: pT1 substaging, particularly the identification of pT1b disease, provides meaningful prognostic information for progression in high-grade T1 bladder cancer. Integrating substaging with key pathological factors such as CIS and tumor size may improve individualized risk stratification and support early risk-adapted treatment decisions.

More From This Issue